OClawVPS.com
OcuMension
Edit

OcuMension

http://www.ocumension.com/
Last activity: 27.08.2024
Active
Categories: Enterprise
眼科,医药,治疗方案,中国眼科医药平台公司,因眼而在,为你而来
Mentions
7
Employees: 11-50
Founded date: 2018

Investors 2

Mentions in press and media 7

DateTitleDescription
27.08.2024Boan Biotech Announces 2024 Half Year Results: Revenue Grows by 39%, Net Profit Increases by RMB 180 MillionYANTAI, China, Aug. 27, 2024 /PRNewswire/ -- Boan Biotech (6955.HK) today announced its 2024 half-year results and latest developments. During the reporting period, the company's total revenue was RMB 363 million, up 39% year-over-year. In ...
12.08.2024Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New HeightsSHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the...
12.08.2024Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New HeightsSHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the...
12.08.2024OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationshipSHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 13th 2024, Ocumension Therapeutics ("OcuMension") announced an agreement with Alcon Inc. ("Alcon", and collectively with OcuMension, the "Parties") where OcuMen...
12.08.2024OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationshipSHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 13th 2024, Ocumension Therapeutics ("OcuMension") announced an agreement with Alcon Inc. ("Alcon", and collectively with OcuMension, the "Parties") where OcuMen...
21.08.2021Ocumension Therapeutics Announces 2021 Interim ResultsCompany loss narrowed sharply by 96% Business Income Increased By More Than 26 Times Year-on-Year Core Product OT-401 Approval Imminent HONG KONG, Aug. 21, 2021 /PRNewswire/ -- The Chinese ophthalmology platform company, Ocumension Therapeu...
20.08.2021Ocumension Therapeutics : Announces 2021 Interim ResultsCompany loss narrowed sharply by 96% Business Income Increased By More Than 26 Times Year-on-Year Core Product OT-401 Approval Imminent HONG KONG, Aug. 20, 2021 /PRNewswire/ -- The Chinese ophthalmology platform company, Ocumension Therapeu...

Reviews 0

Sign up to leave a review

Sign up Log In